Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellbxhealth Plc ADR (OP:ANPCY)

0.2500 +0.0100 (+4.17%)
Streaming Delayed Price Updated: 3:26 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellbxhealth Plc ADR

< Previous 1 2 3 4 5 6 Next >
Angle PLC Announces Issue of Equity
Via ACCESSWIRE
Angle PLC Announces Interim Results
Via ACCESSWIRE
Angle PLC Announces Positive Headline Results From Ovarian Study
Via ACCESSWIRE
Angle PLC announces Study using Parsortix in head and neck cancer
Via ACCESSWIRE
Angle PLC Announces New Poster Presented at ASCP Meeting
Via ACCESSWIRE
Angle PLC Announces Novel Assay; Predicts Malignancy in Pelvic Mass
Via ACCESSWIRE
Angle PLC Announces Notice of Interim Results and Webcast
Via ACCESSWIRE
Angle PLC Announces Issue of Equity
Exercise of Options and Total Voting Rights 
From ANGLE plc
Via AccessWire
Angle PLC Announces Result of 2022 Annual General Meeting
GUILDFORD, SURREY / ACCESSWIRE / June 29, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today,... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Spread of Breast Cancer Accelerates During Sleep
BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP 
From ANGLE plc
Via AccessWire
Angle PLC Announces Issue of Equity
Exercise of Options and Total Voting Rights 
From ANGLE plc
Via AccessWire
Angle PLC Announces Secured Contract From Pharma Services Customer
Additional contract for a new clinical trial 
From ANGLE plc
Via AccessWire
Angle PLC Announces Predicting Immunotherapy Response in SCLC
PARSORTIX SYSTEM DEMONSTRATES POTENTIAL IN PREDICTING IMMUNOTHERAPY RESPONSE IN SMALL CELL LUNG CANCER 
From ANGLE plc
Via AccessWire
Angle PLC Announces Potential Role of Invasive Cellular Protrusions
Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development 
From ANGLE plc
Via AccessWire
Angle PLC Announces Partnership with Major United States Urology Group
PARTNERSHIP ESTABLISHED WITH A MAJOR UNITED STATES UROLOGY GROUP TO CONDUCT CLINICAL STUDIES IN PROSTATE CANCER AND AS A POTENTIAL ROUTE TO MARKET 
From ANGLE plc
Via AccessWire
Angle PLC Announces Molecular Characterisation of CTCs
Parsortix system harvests intact CTCs for single-cell whole genomic sequencing from frozen and fresh blood samples with the same efficiency 
From ANGLE plc
Via AccessWire
ANGLE receives FDA clearance for Parsortix
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEMFDA De Novo product clearance to harvest cancer cells from blood for subsequent analysis offers the prospect of a new era of... 
From ANGLE plc
Via AccessWire
Angle PLC - Prostate Cancer UK Funds New Study Using Parsortix
Research Into the Use of Parsortix-Based CTC Blood Test To Assess Whether Prostate Cancer Patients Require Prostatectomy SurgeryPotential for a New Standard of Care in an Area of High Unmet Medical... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Preliminary Results
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From ANGLE plc
Via AccessWire
Angle PLC Announces Notice of Preliminary Results and Webcast
GUILDFORD, UK / ACCESSWIRE / April 20, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2021 on... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Poster on Parsortix System Presented at AACR 2022
PARSORTIX SYSTEM RESULTS PUBLISHED AS A POSTER AT LEADING CANCER CONFERENCE AACR 2022 Poster demonstrated use of Parsortix workflow for triple negative breast cancer GUILDFORD, UK / ACCESSWIRE / April... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Identifying Drug Targets in Cancer Metastasis
PARSORTIX SYSTEM DEMONSTRATES ABILITY TO ISOLATE CTCs FOR DOWNSTREAM MOLECULAR ANALYSIS, IDENTIFYING KEY DRUG TARGETS INVOLVED IN CANCER METASTASIS - World-class research identifies specific genetic... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Rapid Information on Patient Response to Therapies
PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS - Existing chemotherapies, such as vinorelbine, may selectively target and reduce... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Identifying Therapeutic Targets in TNBC Patients
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER - Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Update on Laboratory Accreditation
ANGLE's US clinical laboratory issued Certificate of Registration, a key step to achieving CLIA accreditation GUILDFORD, UK / ACCESSWIRE / March 15, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Holding(s) in Company
GUILDFORD, SURREY / ACCESSWIRE / March 2, 2022 / ANGLE plc (OTCQX:ANPCY )(AIM:AGL) TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0034330679 Issuer Name ANGLE plc UK or... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Issue of Equity
Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / February 18, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Potential in Immunotherapy Treatment Selection
PEER-REVIEWED PUBLICATION HIGHLIGHTS POTENTIAL FOR PARSORTIX SYSTEM IN IMMUNOTHERAPY TREATMENT SELECTION Parsortix isolation of CTCs highlights relationship between PD-L1 expression and epithelial to... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Concordance of Parsortix with tissue biopsy
BREAKTHROUGH STUDY DEMONSTRATES FOR THE FIRST TIME CONCORDANCE OF PARSORTIX LIQUID BIOPSY BLOOD TEST WITH INVASIVE TISSUE BIOPSY OF THE METASTATIC SITE Study explores key unmet medical need for... 
From ANGLE plc
Via AccessWire
Angle PLC Announces Update on Lab Accreditation and Ovarian Study
First submissions made in relation to accreditation of ANGLE clinical laboratories Ovarian cancer study sample analysis slower than planned GUILDFORD, SURREY / ACCESSWIRE / January 13, 2022 / ANGLE plc... 
From ANGLE plc
Via AccessWire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.